Scancell Holdings PLC (LON:SCLP) shares gained today after the firm said a study has shown that using Oncimmune Holdings PLC's autoantibody technology can successfully predict the recurrence of disease in patients undergoing its SCIB1 treatment for malignant melanoma.
The study, which included a team at the University of Nottingham, used a panel of seven tumour associated autoantibodies to predict disease recurrence in patients with resected stage III/IV melanoma treated with SCIB1.
The results revealed that using Oncimmune's autoantibody platform made it possible to differentiate patient responses to the skin cancer treatment, the company said in a statement.
READ: Scancell’s SCIB1 cancer treatment continues to produce strong survival data
Scancell said the additional information provided by the platform may also help to identify patients who are most likely to respond to SCIB1 in future clinical trials.
"If this preliminary data is confirmed in a larger clinical study, it has the potential to improve the design of future clinical trials using SCIB1 by selecting patients most likely to positively respond to our novel treatment and thereby increase the chances of a successful outcome,” said chief executive Dr Richard Goodfellow.
The data was to be presented at the c today.
In July, Scancell told investors that SCIB1 produced remarkable survival data from a Phase I/II clincal trial.
READ: Scancell poised for “significant” year with its immuno-oncology portfolio
In late afternoon trading, Scancell shares were 3.7%, or 0.5p higher at 14.0p.
-- Adds share price --